Rationale Histamine and dopamine contribute to the maintenance of wakefulness. Objective This study aims to conduct an exploratory analysis of the effects of 10 and 50 mg of MK-0249, a novel histamine subtype-3 receptor inverse agonist, and 200 mg of modafinil, a presumed dopaminergic compound, on EEG power spectra during sleep deprivation and subsequent recovery sleep. Methods A total of 25 healthy men were recruited to a double-blind, placebo-controlled cross-over design. EEG power spectra, an electrophysiological marker of changes in sleepiness and vigilance, were obtained at the beginning of wake maintenance tests at two-hourly intervals throughout a night and day of sleep deprivation, which is an established model of excessive sleepiness.
Introduction
Wake and sleep propensity vary with the sleep-wake history (sleep homeostasis) and time of day (circadian phase) and excessive sleepiness is present in conditions such as narcolepsy, untreated sleep apnea, shiftwork sleep disorder and hypersomnia (Leibowitz et al. 2006) . Changes in sleep-wake propensity can be assessed objectively by testing the ability to initiate sleep in the multiple sleep latency test or the ability to maintain wakefulness in the maintenance of wakefulness test (MWT) (Littner et al. 2005) . The spectral composition of the EEG is an electrophysiological correlate of changes in sleepiness and vigilance. It has been shown repeatedly that during sleep deprivation EEG power in theta and delta activity increases and alpha activity decreases (Aeschbach et al. 1999; Akerstedt and Gillberg 1990; Cajochen et al. 1995 ). An analysis of the contribution of circadian phase and time awake during forced desynchrony has confirmed that these changes in the EEG are related to an interaction of a circadian alerting signal, in part reflected in EEG alpha activity, and a signal associated with the increase in sleep pressure during sustained wakefulness, reflected in an increase in delta and theta activity (Cajochen, et al. 2002) . During the day, wakefulness and vigilance is maintained through activating neurotransmitters such as noradrenaline, dopamine, orexin and histamine originating from brainstem and hypothalamic nuclei (Saper et al. 2005) . These neurotransmitter systems are in part under circadian control and as we enter the biological night the strengths of these activating signals dissipate and sleepiness ensues (Dijk and Czeisler 1995) . The extended wakefulness associated with sleep deprivation activates sleep homeostatic processes and associated changes in a variety of sleep regulatory substances, such as adenosine and TNF alpha, which also contribute to increased sleepiness and changes in the EEG (Krueger et al. 2008) .
These neurochemical mechanisms underlying variations in sleep-wake propensity offer potential targets for sleepiness reducing/wake promoting interventions. Classical sleepiness reducing/wake promoting interventions target the noradrenergic/and dopaminergic systems (amphetamine) and adenosine (caffeine). A more recently developed wakefulness promoting compound (modafinil) appears to target the dopaminergic system, although there remains some debate about the precise mechanisms of action and it may currently not be possible to define modafinil by a single mechanism of action (Bonnet, et al. 2005; Qu et al. 2008) .
The histaminergic system is well placed to modify sleepiness because it has widespread projections to many brain areas, is under circadian control and is at least part of the pathway by which orexin exerts its effects on sleep propensity (Haas et al. 2008) . Histaminergic neurons in the tuberomammillary nuclei are silent during NREM and REM sleep and are active during wakefulness, particularly during attentive wakefulness but not during drowsiness (Takahashi et al. 2006) . It therefore appears that the activity of histaminergic neurons is an important contributor to the maintenance of vigilance.
Histaminergic tone is inhibited through the constitutive activity of the H3 receptor, i.e. a pre-synaptic autoreceptor (Haas et al. 2008; Leurs et al. 2005) . Inverse agonists of this receptor will increase the synthesis and release of histamine and can thereby potentially reduce sleepiness in humans. Preclinical studies have shown that antagonists of the H3 receptor can induce wakefulness and that these effects are, unlike the wake-promoting effects of modafinil, abolished in H3 receptor KO mice, demonstrating the very different mechanisms of actions of the two compounds (Parmentier et al. 2007 ). In one clinical study, reduction of sleepiness in narcoleptic patients was observed after the administration of H3 inverse agonists (Lin et al. 2008) . In that study however, no objective EEG data during either wakefulness or sleep were reported and it is currently not known how H3 antagonists and H3 inverse agonists affect the EEG during wakefulness and sleep.
We previously reported that the novel H3 inverse agonist MK-0249, similar to modafinil, exerts significant wake-promoting effects as assessed by the latency to sleep onset during MWTs in a sleep deprivation paradigm (Iannone et al. 2010) . In that report, we did not present data on the quantitative analysis of the EEG during the sleep deprivation or during the recovery sleep. To further characterise the effects of MK-0249 and modafinil on sleep-wake propensity, we analysed EEG power spectra during the MWT (Chapotot et al. 2003) and subsequent recovery sleep, as well as sleep structure. Assessment of sleep following the administration of a wake-promoting compound is important in order to assess any residual alerting effects that may interfere with sleep when it is desired. A primary question of interest in the present analysis was whether these two compounds, which both have wake-promoting effects but very different mechanism of actions, have similar effects on the spectral composition of the EEG during wakefulness and sleep as well as sleep structure.
Methods
This report is based on an exploratory analysis of a randomised, double-blind, double-dummy, placebo-and modafinil-controlled, four-period crossover study (Merck and Co., Inc. Protocol MK-0249 007-01). The aim of the study was to assess the acute wake-promoting effects of MK 0249 using a sleep deprivation model in healthy male volunteers. The primary outcome variable of this study was sleep latency on the MWT, and these data have been reported elsewhere (Iannone et al. 2010 ). Here we report data on the effects of MK-0249 and modafinil on the spectral composition of the EEG during the MWT, sleep structure during recovery sleep as well as effects on the spectral composition of NREM and REM sleep. Details of the protocol can be found in Iannone et al. (2010) .
The 
Subjects
A total of 25 male volunteers were recruited, aged between 18 and 45 years. The participants had a BMI of between 19 and 31 kg/m 2 and were free from any pre-existing pathological conditions including neurological, psychiatric, cardiovascular, respiratory, endocrine, vascular, haematological, gastrointestinal, hepatic, renal and genitourinary and any evidence or history of cancer. They gave written informed consent prior to any study procedures being conducted. A physician judged each participant to be healthy based on their ECG, medical history, physical examination, haematology, blood chemistry and urinalysis tests. The participants discontinued any medications for 14 days prior to day 1 and throughout the study. Those that were unable to do this were excluded from the study, with the exception of treatment for minor ailments. They showed no evidence of epileptic EEG activity during screening. During an acclimatisation stay in the unit, the participants who fell asleep within 15 min of a 20-min Maintenance of Wakefulness Test (MWT) after approximately 25 h of continuous wakefulness were eligible for inclusion. The participants who smoked more than five cigarettes per day were not eligible and smoking was not allowed while the participants were in the laboratory. The participants agreed not to consume any caffeinated beverages for 24 h prior to each admission into the Surrey CRC and for the duration of their stay. They had not travelled through any time zones for 14 days prior to their acclimatisation stay and throughout the study. They were not shift workers, did not suffer from any sleep disorders, were deemed to have normal sleep habits and typically commenced habitual sleep between 20:00 h and 00:00 h.
Protocol
During each of the four treatment periods of the study, the participants had an 8-h baseline sleep opportunity from 23:00 h to 07:00 h and were then kept awake until 21:00 on day 2, resulting in 38 h of continuous wakefulness, at which time they commenced a 12-h recovery sleep opportunity (Fig. 1) .
MWTs were performed in a sound-attenuated, lightcontrolled individual bedroom at 08:00 h on day 1 and at two-hourly intervals from 00:00 h until 20:00 h on day 2, as illustrated in Fig. 1 . The participants also completed a series of psychometric tests as part of the protocol, the results of which are presented in Iannone et al. (2010) . During times when the participants were not completing tests, they were allowed to move around in the unit and carry out various activities such as watching TV, playing games and reading. These activities were strictly controlled and consistent throughout the study periods. To ensure that the subjects were awake, they were under continuous surveillance and not allowed to sit in comfortable chairs. Drug administration occurred at 02:00 h on day 2 and consisted of a single dose of either 200 mg of modafinil, 10 or 50 mg of MK-0249 or placebo. Doses of 10 and 50 mg of MK-0249 are expected to result in 88% and 93% receptor occupancy respectively (Iannone et al. 2010) . Administration was carried out in a double-blind, doubledummy fashion and there was a washout period of at least 7 days between each of the four treatment periods.
EEG recordings during MWTs and sleep episodes
All PSG recordings for both sleep and waking EEG were electronically captured through the Siesta system (Compumedics, Abbotsford, Victoria, Australia). The montage for this study were C3-A2, C4-A1, O1-A2 and O2-A1, in addition to two EMG and two EOG channels for both sleep and wake recordings. All EEG signals were low-passfiltered at 70 Hz and high-pass-filtered with a time constant of 0.33 s which corresponds to a cutoff frequency of 0.53 Hz. The sampling rate was 256 Hz and the data were stored at 128 Hz for EEG, EOG and EMG signals. Data collected on the Siesta system was transmitted via Bluetooth and recorded directly to a computer file server and later downloaded into EDF files.
Spectral analysis
All wake and sleep EEG recordings were visually inspected and 2-s (MWT) or 4-s epochs (sleep EEG) containing artefacts were annotated manually using Vitascore software (Temec, The Netherlands). Epochs annotated as artefacts were excluded from the analysis of the power spectra. Spectral analysis was conducted using a fast Fourier transform after the data were weighted with a squared cosine window implemented in the Vitascore software. Power spectra were computed per 2 s, resulting in a 0.5-Hz resolution for the MWT EEGs. For the sleep EEG, spectra were computed per 4 s, resulting in a 0.25-Hz resolution.
Scoring and processing of MWT EEG data
The first 2 min of EEG which was free from any significant movement artefact within the first 5 min of each MWT were selected by the first author for analysis. Any further artefacts were then manually removed from these 2-min periods of data. At least 20 s of data had to be available after artefact removal for data to be included in the final dataset of power density values. It was considered that any less than this may not have given an accurate representation of the EEG being sampled. An analysis of these 2-min periods was carried out regardless of vigilance state and for waking EEG only. In this report, EEG data during the MWT will be presented independent of vigilance state.
Scoring and processing of sleep EEG data
A 12-h recovery sleep episode commenced at 21:00 h on day 2, after 38 h of continuous wakefulness and 19 h after drug administration (Fig. 1) . Sleep stages and power spectra data were analysed to assess the effects of both 10 and 50 mg of MK-0249 and modafinil on recovery sleep, compared to placebo. Sleep records were scored by the first author on a 30-s epoch basis according to the established criteria of Rechtschaffen and Kales (1968) . From this standard, sleep parameters were calculated. They include latencies to sleep onset, defined as the first occurrence of stages 2, 3, 4 or REM sleep, the duration of stages 1, 2, 3, 4, SWS and REM sleep, number and duration of sleep cycles, total sleep time (TST), sleep efficiency, i.e. TST/ time between lights-off and lights-on, the number of sleep stage changes, the number of awakenings (NAW) and wake-after-sleep onset (WASO). EEG data were subjected to FFT power density spectral analysis, as described above and sleep stage-specific power spectra were computed. Data for the entire 12-h recovery sleep episode were analysed in addition to the first 8 h of the sleep episode in order to assess the effects of an extended recovery sleep opportunity and a typical 8-h sleep opportunity, both of which may represent 'real-life' scenarios.
Statistics
A statistical analysis plan for these exploratory analyses was established prior to review of the data. All statistical analyses were carried out using SAS®, version 9.1.
Analysis of MWT data
In order to assess the effect of sleep deprivation, spectral data of each MWT in each subject were expressed relative to the baseline of this subject, which was the average of MWTs 1, 2 and 3. These analyses were conducted with a resolution of 1 Hz. Ratios were log-transformed and differences from baseline were assessed by a Student's t-test.
To assess the effects of the various treatments, values in each MWT and each frequency bin were expressed relative to the corresponding placebo value. A paired Student's t-test was used to assess the significant differences from placebo at each frequency from 1 to 25 Hz on log-transformed data. The level of significance used throughout was 0.05 and no correction for multiplicity was made. This obviously increases the likelihood of false positives. We nevertheless feel that this approach is justified because (a) this is an exploratory analyses, (b) it will allow for a direct comparison to previous studies, e.g. (Tinguely et al. 2006) , (c) spectral values of adjacent frequency bins are highly correlated which makes selecting the appropriate correction for multiplicity problematic and (d) there is prior knowledge on the effects of sleep deprivation and modafinil on EEG power spectra on the MWT.
Visual inspection of the data shows that the significant effects are clustered in specific frequency ranges in accordance with prior studies and are unlikely to reflect statistical artefact.
Analysis of sleep EEG data

Sleep stages
Comparisons between conditions were made using SAS PROX MIXED with treatment and period as fixed factors and subject as a random factor, followed by the LS MEANS statement to compute the p-value of the contrast between conditions. The significance level used throughout was 0.05.
EEG power spectra during sleep
Power density spectra were created and a paired Student's ttest was used to assess significant differences from placebo at each frequency from 1 to 25 Hz on log-transformed data for the sleep stage-specific spectral data. The differences between treatment groups and placebo for PSG measures were also assessed using a linear mixed-effects model.
One of the 25 enrolled subjects dropped out after period 1 and was subsequently replaced and not included in the EEG analysis. Thus, 24 subjects were included in the analyses but please note that for some of the comparisons the number of subjects may be less than 24 due to missing data.
Results
Effects of sleep deprivation on EEG power spectra at the beginning of MWT To document the effects of sleep deprivation on the EEG during the MWT, the EEG spectral data following dosing with placebo were expressed relative to the data collected pre-dosing, i.e. at MWT1 at 08:00, MWT2 at 0:00 and MWT 3 02:00 (see Fig. 1 ). Sleep deprivation led to a substantial increase in low-frequency activity, from 1 to 7 Hz, in both central and occipital derivations (Fig. 2) . The changes were observed from 2 to 6 h post-placebo dose, 8 to 12 and 14 to 18 h post-dose. Evidence for a progressive increase in EEG power density was only observed in the 1 and 2 Hz bins, in which values at the later sampling times of 8 to 12 and 14 to 18 h post-dose were greater compared to those of 2 to 6 h post-dose. Sleep deprivation also led to a reduction in alpha activity (10-11 and 10-12 Hz for the central and occipital derivation, respectively). A significant increase in EEG activity with the sigma band was only observed at 14 Hz in the central derivation. Beta activity was reduced between 18 and 22 Hz Effects of MK-0249 and modafinil on EEG power spectra at the beginning of MWT
The effects of the two doses of MK-0249 and modafinil on the EEG were analysed by comparing EEG power spectra in these three active conditions to the placebo condition for both the central (Fig. 3 ) and occipital derivation (Fig. 4) . A comparison of the EEG power spectra pre-dosing (i.e. baseline values) revealed very few differences across conditions. By contrast, post-dosing many differences emerged when the EEG power spectra at the beginning of the MWT were analysed for the interval 2 to 6, 8 to 12 and 14 to 18 h post-dose (Figs. 3 and 4) . In the 2-6 h post-dose interval, modafinil and both doses of MK-0249 reduced low-frequency activity up to approximately 6-7 Hz. During this interval, all three active treatments enhanced alpha and beta activity in both the central and occipital derivation. During the 8-12 and 14 to 18 h post-dose intervals, differences with placebo became smaller in general, whereas in the modafinil condition the reduction of delta and theta activity persisted in the 8-12 and 14-18 h post-dose interval. The spectral values in this frequency range after both doses of MK-0249 were no longer significantly different from placebo during these time periods. By contrast, the effects on alpha and beta activity, in particular, appeared to persist throughout the 18-h post-dose interval for all three active treatments, most clearly so for the highest dose of MK-0249.
Effects of MK-0249 and modafinil on sleep initiation, sleep maintenance and sleep structure following sleep deprivation No significant differences between placebo and modafinil or placebo and either dose of MK-0249 were observed for measures of sleep initiation, i.e. latency to sleep onset and latency to persistent sleep ( Table 1 ). The latency to SWS and REM sleep was also not significantly affected by the active treatments. The number and duration of sleep cycles was neither affected by modafinil nor any of the two doses of MK-0249. Both 10 and 50 mg of MK-0249 reduced total sleep time while modafinil did not. Less SWS and more stage 1 sleep were present after the administration of 10 mg of MK-0249. In addition to these changes, 50 mg of MK-0249 also significantly reduced the percentage of stage 2 sleep, compared to placebo. REM sleep was also reduced by the administration of both doses of MK-0249. Modafinil did not affect any sleep stage, analysed either for the entire 12-h sleep episode (Table 1) or for first 8 h of the recovery sleep episode (Table 2) . Fig. 3 Comparison of the effects of modafinil and MK-0249 with placebo on EEG power spectra during MWTs for 4 h time bins in the central derivation. Central derivation EEG power density spectra of wake and sleep EEG combined for MWTs binned each 4 h for modafinil (red triangles, n=22 in top two panels and n=23 in bottom two panels), MK-0249 10 mg (blue circles, n=24) and MK-0249 50 mg (green squares, n=24) expressed as a percentage of placebo for each MWT time point. Red triangles, blue circles and green squares on the x-axis indicate significant differences between placebo and modafinil, MK-0249 10 mg and MK-0249 50 mg, respectively; p<0.05
The number of sleep stage changes was lower after the administration of 50 mg of MK-0249. No significant differences in the number of awakenings were present after the administration of modafinil or either dose of MK-0249.
However, wake after sleep onset was increased by both doses of MK-0249.
These differences between placebo and active treatments for the entire recovery sleep episode were largely replicated when only the first 8 h of sleep were analysed with the exceptions that the increase in stage 2 sleep after the administration of 50 mg of MK-0249 and the reduction in REM sleep after the administration of 10 mg of MK-0249 did not reach statistical significance when the analysis was limited to the first 8 h.
Effect of modafinil and MK-0249 on EEG power spectra in NREM and REM sleep during recovery sleep
The effects of the treatments on the spectral composition of the EEG were investigated by analysing the power spectra per third of the 12-h sleep episode, for the central and occipital derivation and separately for NREM (Fig. 5 ) and REM sleep (Fig. 6 ). The analysis revealed that modafinil had no consistent effects on EEG power spectra during either NREM or REM sleep in any of the intervals and derivations analysed. By contrast, both doses of MK-0249 reduced very-lowfrequency (0.25-2.0 Hz) activity and increased high spindle and beta activity in NREM sleep in both the central and occipital derivation. The latter effects were most pronounced for the highest dose. The enhancement of beta activity and the reduction of low delta during NREM sleep persisted throughout the 12-h sleep episode primarily after the higher dose of MK-0249 and in both central and occipital derivation. Furthermore, the higher dose of MK-0249 reduced theta activity at 7 and 8 Hz during NREM sleep, but this effect was observed only in the central derivation.
Dose-dependent effects of MK-0249 on EEG power spectra during REM sleep were observed. The highest dose of MK-0249 led to an enhancement of beta activity during REM sleep which was primarily observed in the central deprivation. The highest dose reduced very-low-frequency and theta activity which was primarily observed in the occipital derivation. The analysis per third of the night did not suggest that these effects on EEG power spectra dissipated in the course of the sleep episode.
Discussion
The effects of sleep deprivation on EEG power spectra during the MWT as observed in the present study are in accordance with previous reports showing enhancement of low-frequency EEG activity and reduction in alpha activity during the MWT (Chapotot et al. 2003) or during the Karolinska Drowsiness Test (KDT) with eyes open (Akerstedt and Gillberg 1990) (Aeschbach et al. 1999 ). These effects persisted throughout the entire sleep deprivation period. Whereas in some previous reports sleep deprivation was associated with an increase in beta activity (Dumont et al. 1999 ), a decrease in beta EEG activity was observed in the present study. In the present study, we also observed an increase in sigma activity. These minor discrepancies may be related to the use of the MWT vs. the KDT. Overall, the robust effects of sleep deprivation on the EEG power spectra at the beginning of the MWT, which can be summarised as an increase in delta and theta activity and a reduction in alpha activity, demonstrate the sensitivity of this method for detecting changes in vigilance under placebo conditions.
The effects of both MK-0249 and modafinil on EEG power spectra at the beginning of the MWT can be summarised as 'countering the effects of sleep deprivation'. Thus, the "drug induced-wakefulness" or "pharmacological sleep deprivation" was characterised by effects which were to a large extent a mirror image of the effects of sleep deprivation under placebo. In the first 6 h post-dose, both compounds reduced delta and theta activity and enhanced alpha activity. In addition, the compounds enhanced beta activity. Modafinil-induced reduction of delta and theta activity was previously reported in a helicopter simulator study (Caldwell et al. 2000) , although in that study no enhancement of alpha or beta activity was reported. In a previous sleep deprivation-MWT study (Chapotot et al. 2003) , modafinil was reported to enhance alpha activity but not beta activity. Modafinil also reduced theta activity in that study and although significantly so, only at a few time points. In that study, the effects of the stimulant d-amphetamine were also assessed and it was found that d-amphetamine reduced theta activity throughout the sleep deprivation but did not significantly enhance alpha activity. Based on these previous studies with modafinil and d-amphetamine, as well as the effects of the stimulant caffeine (Landolt et al. 2004) , and the effects of sleep deprivation under placebo, it can be concluded that a reduction of the delta and theta enhancement of alpha activity are part of an alerting EEG signature. The effects of MK-0249 on the EEG to a large extent encompass this alerting EEG signature. Not much evidence for a dose effect was found and this may indicate that the lower dose of MK-0249 has already near-maximal effects. In the first 6 h post-dose, the effects on EEG power spectra were very similar for modafinil and MK02409, despite their different mechanism of action.
The observed differences between modafinil and MK-0249 with respect to the time course of the effects on EEG powers spectra appeared to be frequency specific. The enhancement of beta activity, and to some extent alpha activity, persisted throughout the 18-h post-dose period for all active treatments. The reduction in delta and theta activity remained significant for approximately 14 h postdose period after modafinil administration but only for the first 4 h or so after MK-0249. These frequency-specific differences may relate to the different mechanisms of action or different pharmacokinetics of the two drugs.
During recovery sleep, initiated 19 h following dosing with MK-0249, EEG power spectra in both NREM and REM sleep were altered relative to baseline. The effects differed between REM and NREM sleep and between the doses; for REM sleep, the effects appeared to depend on EEG derivation as well. Sleep stage and EEG derivationspecific effects have previously been reported after other pharmacological interventions. The effects of MK-0249 on EEG power spectra during NREM sleep and REM sleep are very different from the effects of compounds such as benzodiazepine and non-benzodiazepine agonists of the synaptic and extra-synaptic GABA receptor (Borbely et al. 1985; Brunner et al. 1991; Dijk et al. 2010; Trachsel et al. (Dijk et al. 1989; Landolt et al. 1999 ) and alcohol (Dijk et al. 1992) . The effects of MK-0249 and of the higher dose, in particular, on EEG power spectra during NREM sleep probably reflect residual alerting effects because the number of awakenings and wake after sleep onset were also increased relative to placebo. These effects were, however, relatively mild because sleep onset and the number of awakenings were not affected, although sleep efficiency, SWS% and REM% were suppressed. Thus, our data suggests that modulation of the histaminergic system by MK-0249 appears to affect cortical activation and vigilance state.
EEG power spectra during NREM sleep and REM sleep were not affected by modafinil, even though analysis of the MWT EEG data suggested some maintained efficacy up to 18 h post dose, i.e. 1 h prior to the start of recovery sleep. This may indicate that the effects of modafinil on sleep EEG power spectra differ from its effects on the EEG during wakefulness. In other words, the effects of modafinil on the EEG are vigilance state specific: modafinil affects the EEG during wakefulness but not during sleep. Alternatively, these observations may simply imply that, at 19 h post-dose, the wake-promoting effects of modafinil, with a half-life of 10-12 h, have dissipated too much to still affect the sleep EEG, and the effects of MK-0249, with a half-life of approximately 14 h, may still be present. The lack of an effect of modafinil compared to placebo, on the EEG during recovery sleep following sleep deprivation, contrasts to the effects of, for example, caffeine administration during sleep deprivation. Caffeine, in contrast to modafinil, does not just inhibit the expression of a sleep debt but rather reduce the build-up of sleep pressure during wakefulness (Landolt et al. 2004) . The lack of an effect of modafinil on EEG power spectra during NREM sleep is in accordance with the absence of an effect on sleep structure and sleep maintenance measures. These findings are in accordance with previous studies from which it was concluded that modafinil does not disrupt sleep if administration takes place 10 h or more before the start of sleep (Bonnet et al. 2005) . Please note that after neither MK-0249 nor modafinil, the rebound of SWS or TST following sleep deprivation exceeds the placebo values.
Overall, the data show that the H3 inverse agonist MK 0249 has robust effects on the EEG during sleep deprivation, as well as effects on the EEG during sleep. The latter effects appeared dose dependent and may also depend on the mechanisms of action of the two compounds. Despite the very different mechanism of action of modafinil and MK-0249, the effects of the two compounds on the EEG during sleep deprivation were rather similar. These data support the notion that H3 inverse agonists, similar to modafinil, have robust wake-promoting effects. Effects of modafinil and MK-0249 on EEG REM power density spectra per third of the night. Power density spectra expressed as a percentage of placebo for the first (left), second (middle) and third (right) thirds of the recovery night for central (top row) and occipital (bottom row) derivations after the administration of modafinil (red lines and filled triangles, n=21 in a to e and n=20 in f), MK-0249 10 mg (blue lines and open circles, n=22 in a to e and n=21 in f) and MK-0249 50 mg (green lines and filled squares, n=22 in b and c and n=21 in a, e and f). Red triangles, blue circles and green squares along the x-axis indicate a significant difference between placebo and modafinil, MK-0249 10 mg and MK-0249 50 mg, respectively; P< 0.05
